Product image of Medimibi (Tetrafluoroborate) supplied by GNH India

Medimibi

Active Ingredient:
Tetrafluoroborate
Origin:
EU

Medimibi (Tetrafluoroborate)

Tetrafluoroborate, the active ingredient in Medimibi, is a pharmaceutical compound presented as an intravenous formulation for clinical use. It has not been assigned a specific drug class and its therapeutic applications are not publicly disclosed.\n\nGNH India supplies Medimibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Radiopharmacy Laboratórium Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Medimibi (tetrafluoroborate) currently has no publicly listed therapeutic indications.\n\nInvestigational Use: under study for potential therapeutic applications\nLaboratory Research: employed as a chemical probe in cellular studies\nPreclinical Models: used in animal studies to explore pharmacodynamics

How It Works

  • The precise mechanism of action of tetrafluoroborate in Medimibi has not been publicly disclosed. Available information suggests it may interact with cellular ion channels or enzymatic pathways, but detailed pharmacodynamic data are lacking.

Side Effects

  • Adverse reactions associated with Medimibi have not been fully characterized.\n\nCommon Side Effects:\n- Data not available: specific common adverse events have not been reported\n- Data not available: frequency and severity are unknown\n\nSerious or Rare Side Effects:\n- Data not available: serious adverse events have not been documented\n- Data not available: rare reactions remain uncharacterized

Precautions & Warnings

  • General safety considerations for Medimibi include:\n\nPrescriber Evaluation: assess patient history and clinical context before use\nMonitoring: observe for any unexpected reactions during administration\nAllergy Check: verify no known hypersensitivity to tetrafluoroborate or formulation components\nCompatibility: ensure appropriate IV line and diluent compatibility\nStorage: Store at ambient temperature: keep in original container, protect from moisture and direct sunlight

Avoid Interactions

  • Potential drug interactions for Medimibi are not well defined.\n\nMajor Interactions (Avoid):\n- Data not available: no documented major interacting agents\n- Data not available: avoid co‑administration with unknown contraindicated substances\n\nModerate Interactions (Monitor Closely):\n- Data not available: monitor for any pharmacodynamic changes when combined with other IV therapies\n- Data not available: observe renal or hepatic function if used with metabolically active drugs

Frequently Asked Questions

Medimibi contains tetrafluoroborate and is primarily employed in research and investigational settings. It is not approved for specific therapeutic indications, but it may be used as a chemical probe in laboratory and preclinical studies.

The exact pharmacological mechanism of tetrafluoroborate in Medimibi has not been disclosed. Current hypotheses suggest interaction with cellular ion channels or enzymatic pathways, though detailed mechanisms remain under investigation.

Dosing of Medimibi is determined by the prescribing clinician based on the specific research protocol or investigational study. No standardized dosing regimen is publicly available.

Safety data for Medimibi in pregnancy or lactation are lacking. Until more information is available, it should be used with caution and only if the potential benefits outweigh any possible risks, under professional guidance.

To request Medimibi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Medimibi’s tetrafluoroborate component differs from other research compounds in its chemical structure and proposed interaction with ion channels. Direct efficacy or safety comparisons are not available because it is not approved for clinical use.

Store Medimibi at ambient temperature, in its original packaging, protected from moisture and direct sunlight. Follow standard good distribution practice (GDP) guidelines for injectable products and avoid freezing the solution.

Medimibi is supplied for intravenous administration. It should be infused according to the protocol defined by the supervising researcher or clinician, using appropriate sterile techniques and compatible IV equipment.

Serious risks are not well defined due to limited clinical data. Potential concerns include unexpected adverse reactions during IV infusion, hypersensitivity, and unknown organ toxicity. Continuous monitoring is advised during use.

Individuals with known hypersensitivity to tetrafluoroborate or any component of the formulation should avoid Medimibi. Additionally, it is not recommended for patients outside of a controlled research environment without appropriate oversight.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrafluoroborate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT